These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 31294640)
21. Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review. Rhee JY; Tremblay D; Chan AM; Tallman MS; Mascarenhas J Blood Adv; 2019 Jun; 3(12):1854-1857. PubMed ID: 31213431 [TBL] [Abstract][Full Text] [Related]
22. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide. Galm O; Fabry U; Osieka R Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758 [No Abstract] [Full Text] [Related]
23. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Barbey JT; Soignet S Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116 [No Abstract] [Full Text] [Related]
24. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological. Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042 [TBL] [Abstract][Full Text] [Related]
25. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia. Zhang Y; Wu S; Luo D; Zhou J; Li D PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490 [TBL] [Abstract][Full Text] [Related]
26. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399 [TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide. Jin B; Zhang Y; Hou W; Cao F; Lu M; Yang H; Tian X; Wang Y; Hou J; Fu J; Li H; Zhou J J Cancer Res Clin Oncol; 2020 Feb; 146(2):485-492. PubMed ID: 31686248 [TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. Gill H; Yim R; Lee HKK; Mak V; Lin SY; Kho B; Yip SF; Lau JSM; Li W; Ip HW; Hwang YY; Chan TSY; Tse E; Au WY; Kumana CR; Kwong YL Cancer; 2018 Jun; 124(11):2316-2326. PubMed ID: 29579321 [TBL] [Abstract][Full Text] [Related]
29. Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia. Imagawa J Leuk Lymphoma; 2018 Dec; 59(12):3013-3015. PubMed ID: 29616847 [No Abstract] [Full Text] [Related]
30. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide. Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140 [TBL] [Abstract][Full Text] [Related]
31. [Acute kidney failure in differentiation syndrome: a possible complication during therapy with differentiating agents for acute promyelocytic leukemia. A case report]. Di Micco L; Mirenghi F; Morelli E; De Simone E G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373469 [TBL] [Abstract][Full Text] [Related]
32. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected]. Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176 [No Abstract] [Full Text] [Related]